The Drug-Induced Respiratory Disease Website and App

Rituximab-CHOP regimen (R-CHOP)

See under specific drugs of the regimen, including the anti-CD20 Rituximab. Under this heading are cases where the responsibility of any of the drugs composing the R-CHOP could not be confidently sorted out

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I - Interstitial/parenchymal lung disease

I.b

Pneumonitis (interstitial lung disease/ILD)

I.d

Organizing pneumonia pattern (an area or areas of consolidation on imaging)

III - Pulmonary/alveolar./airway hemorrhage/bleeding

III.a

Alveolar hemorrhage (AH), diffuse AH (DAH)

XV - Pathology

XV.a

Path: NSIP-cellular pattern (see also Ia, Ib)

XVI - Imaging

XVI.u

Imaging: A miliary pattern (diffuse random micronodules)

XVII - Infections & related conditions

XVII.g

Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo